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Summary The polyanionic compound suramin can inhibit the proliferation of cells of various origin,
including from breast cancer. We have studied the effects of suramin on cell cycle kinetics and distribution of
MCF-7 human breast cancer cells in vitro. It was found that both under serum-containing and serum-free
culture conditions, and in the absence or presence of oestradiol or insulin-like growth factor-i, prolonged
exposure (>48 h) to suramin caused an accumulation of surviving cells in the G2/M-phase of the cell cycle. At
a concentration of more than 100 lIg ml-' suramin significantly inhibited cell proliferation. The observed
effects of suramin on breast cancer cells in vitro, i.e. antiproliferative effects and accumulation of cells in the
G2/M-phase of the cell cycle, may have beneficial consequences in the application of treatment strategies based
on a combination of suramin with cell cycle specific drugs or radiation therapy.
The polysulphonated naphthylurea suramin has been shown
to inhibit the proliferation of a variety of human cancer cell
lines cultured in vitro. Among these cell lines are those from
known endocrine target organs as the prostate, ovary and the
breast (Berns et al., 1990; Freuhauf et al., 1990; LaRocca et
al., 1990, 1991; Olivier et al., 1990; Foekens et al., 1992;
Vignon et al., 1992). Suramin acts probably mainly extracel-
lularly by interference in the binding of growth factors to
their receptors (Betsholtz et al., 1984; Coffey et al., 1987),
including several which are known to be involved in breast
tumour growth or development, i.e. epidermal growth factor
(Coffey et al., 1987; Berns et al., 1990; Kopp & Pfeiffer, 1990;
Vignon et al., 1992), transforming growth factor-P (Coffey et
al., 1987), fibroblast growth factors (Coffey et al., 1987;
Coughlin et al., 1988; Foekens et al., 1992), and insulin-like
growth factors (Pollak & Richard, 1990; Foekens et al., 1992;
Vignon et al., 1992). In addition, direct intracellular effects
can not be excluded (Spigelman et al., 1987). We have
studied the effect of suramin on cell cycle kinetics of human
breast cancer cells in vitro to shed some light on its
mechanism of action and because of the current interest in
using suramin and suramin-like compounds as anticancer
agents in patients with cancer from various origins (Car-
michael et al., 1987; Stein et al., 1989; Vierhapper et al.,




Suramin, the hexasodium salt of 8,8'-(carbonylbis[imino-3,1-
phenylenecarbamylimino(4 -methyl -2,1 -phenylene)carbonyli-
mino]}-bis-1,3,5-naphthalenetrisulfonic acid was purchased
from FBA, Bayer AG, Leverkusen, Germany). Human re-
cominant insulin-like growth factor-1 was a generous gift of
Dr K. Muller (Ciba-Geigy AG, Basel, Swizerland). Culture
media were from Sigma Corporation (St Lous, Mo, USA),
penicillin/streptomycin, glutamine and trypsin-EDTA were
from Northumberland Biologicals Ltd (UK), porcine insulin
from Organon BV (Oss, The Netherlands), gentamycin from
Sebak (Aidenbach, Germany), and fetal calf serum and
bovine calf serum (iron-supplemented) were purchased from
HyClone Laboratories Inc (Utah, USA). Purified bovine
serum albumin (BSA) was obtained from Behringwerke AG
(Marburg, Germany). [3-(5-5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium-bromide] (MTT) was purchased from
Sigma, St Louis, Mo, USA). Bromodeoxyuridine was
obtained from Serva (Heidelberg, Germany).
MCF-7 human breast cancer cells, obtained from the
ATCC (Rockville, Md, USA), were routinely grown in com-
plete growth medium, consisting of RPMI-1640 medium,
containing phenol red and 10% heat-inactivated (30 min
56°C) bovine calf serum, NaHCO3 (10 mM), HEPES
(20mM), glutamine (2mM), penicillin (100Umlm'), strepto-
mycin (100 I g ml- 1), gentamycin (45 pg ml-'), and insulin
(10ggml-'). Steroid-depleted medium consisted of DMEM/
HAM F-12 medium (without phenol red), and supplemented
with NaHCO3 (10 mM), HEPES (15 mM), glutamine (2 mM),
penicillin (100 U ml-'), streptomycin (100 jig ml-1), gentamy-
cin (45ggml-'), and 2.5% dextran-coated charcoal treated
fetal calf serum. For serum-free medium, fetal calf serum was
replaced by 0.2% BSA and Na2Se203 (50 ngml-').
Methods
Cell proliferation assay Cells in approximately 75%
confluent cultures were harvested by trypsinisation (5 min at
37°C with 0.5 ml trypsin/EDTA: 0.05%/0.02% in 2 ml of
PBS), resuspended in fresh medium and plated in 96-wells
microtiter plates (Greiner, Alphen a/d Rijn, The Nether-
lands), and incubated for the time period as indicated in the
legend to the figures to allow attachment and flattening of
the cells. Subsequently, experimental medium was added and
following incubation (eight wells for each condition studied),
the wells were washed twice with phosphate-buffered saline
(PBS) before MTT was added to measure the amount of
viable cells (Carmichael et al., 1987). There was a linear
relationship between the MTT-assay and cell number within
the range of the experiments.
Assessment of cell cycle distribution The effects of suramin
on cell cycle kinetics was studied by use of dual-parameter
flow cytometry following bromodeoxyuridine incorporation,
a measure of cells actively synthesising DNA, and propidium
iodide uptake. Cells were cultured in duplicate incubations in
25 cm2 flasks (5-10 x I05 cells/flask). Bromodeoxyuridine at
a final concentration of 10 gLM was added to the cultures
30 min before harvesting. After this incubation cells were
washed twice and harvested by trypsinisation, followed by
the addition of 1 ml trypsin inhibitor (0.1 mg ml1; Sigma, St
Louis, Mo, USA) in PBS. The cell pellets were stored in 2 ml
of 70°C ethanol (- 20C) before preparation for analysis of
cell cycle distribution by dual-parameter (anti-bromo-
deoxyuridine-FITC/propidium iodide) flow cytometry, per-
formed as described previously (Bontenbal et al., 1989).
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Figure 1 Effect of suramin on the proliferation of MCF-7 cells
in complete growth medium. Cells were seeded in 96-wells micro-
culture plates at a density of 2,500 cells/well in complete growth
medium. After 24 h, fresh complete growth medium in the absence
and presence of increasing concentrations of suramin was added
and cells were cultured for 5 days, with medium renewal at day 3.
The results ofdata obtained with the MTT-assay are expressed as
the fraction of control ± standard error of the quotient vs
suramin concentration.
The results are expressed as mean ± intraexperimental
standard errors or standard deviations. The figures shown are
examples of at least two or three individual experiments, all
pointing at the same direction.
Results
Figure 1 shows a dose-dependent inhibitory effect of suramin
on the proliferation of MCF-7 cells after 5 days incubation in
complete growth medium. This figure merely reflects an
inhibition of growth since the majority of the cells in
suramin-containing cultures did not grow at the same rate as
those in the exponentially growing control cultures. At all
concentrations of suramin used, the absolute number of
viable cells after 3 days was higher than originally plated
(data not shown), suggesting that suramin is not cytotoxic
but rather cytostatic.
Effects ofsuramin on cell cycle kinetics in complete growth
medium
Cells were cultured in complete growth medium and cell cycle
distribution was assessed after 1, 2, 3, 6' and 9 days of
permanent exposure to different concentrations of suramin.
Figure 2 shows there was a time and dose-dependent increase
of the fraction of cells in the G2/M-phase, reaching nearly a
plateau phase after 6 to 9 days of exposure to suramin. At
the two highest concentrations of suramin (1 and 5 mg ml-1)
used, there were not enough cells left after 9 days as a
consequence of growth arrest and loss of cells due medium
renewal twice, to allow for a meaningful analysis of cell cycle
distribution by flow cytometry. Together with the observa-
tion that there was a dose-dependent decrease in the fraction
of cells in the GO/GI and S-phases (data not shown), these
data suggest that during culture in complete growth medium
surviving cells accumulate and arrest in the G2/M-phase of
the cell cycle upon suramin exposure. At present it can
however not be excluded whether the observed increase in the
fraction of G2/M-phase cells was due to a selective kill of
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Figure 2 Effect of suramin exposure on the kinetics ofaccumulation of MCF-7 cells in the G2/M-phase of the cell cycle. Cells were
seeded in complete growth medium and allowed to attach for 24 h before experimental complete growth medium containing
increasing amounts of suramin, as indicated, was added. At days 1, 2, 3, 6 and 9, cells were harvested and assayed for the fraction
of G2/M-phase cells. Medium was renewed at days 1, 2, 3 and day 6. Results are expressed as the percentage of G2/M-phase
cells ± standard deviation vs days of suramin exposure.234 J.A. FOEKENS et al.
Combinedeffects ofsuramin, oestradiol and IGF-J, on cell
cycle kinetics
To study the combined effects of suramin and two known
potent mitogens for breast cancer cell growth (oestradiol and
IGF-l) on cell cycle kinetics of MCF-7 cells, experiments
were performed in serum-free medium and in medium con-
taining dextran-coated charcoal treated serum. After a 24 h
incubation in serum-free medium in the presence of oest-
radiol (0.1 and 1 nM) or IGF-l (10 and 100 ngml-') the
fraction of S-phase cells was significantly increased in the
absence of suramin (36-48% S-phase cells in the stimulated
cultures vs 12% in the control cultures) (Figure 3). During
the first 24 h, both in the absence and in the presence of
oestradiol, suramin caused an increase of cells in the S-
phase of the cell cycle. In contrast, the increase in the
S-phase fraction caused by IGF-1 was inhibited by suramin
in a dose-dependent way (Figure 3). Regarding the latter,
0.1 mgml-' of suramin was effective only in inhibiting the
stimulation caused by the lowest concentration of IGF-1
(l0ngml-') used. Only with the highest concentration of
suramin (1 mgml-') the stimulation caused by 100 ngml-'
of IGF-1 was also inhibited to a similar extent. Comparable
to incubation in complete growth medium (Figure 2), also in
medium containing dextran-coated charcoal treated serum,
suramin caused a time-dependent accumulation of MCF-7
cells in the G2/M-phase of the cell cycle (Figure 4, top). This
accumulation was not yet apparent at 24 h since the cells in
the oestradiol and IGF-1 stimulated cultures were mainly
present in the S-phase, which has also been shown in Figure
3 in serum-free medium. After progression through the cell
cycle, the cells accumulated in the G2/M-phase which became
apparent at 48 and 72 h (Figure 4). In the absence of
suramin and in the presence of 1 nM oestradiol or
lOOngml-l IGF-1, a gradual increase in the fraction of
GO/G, cells was observed between 24 and 72 h, after an initial
decrease during the first 24 h of incubation (Figure 4, bot-












GO/G, cells was not followed by a subsequent increase
between 24 and 72 h (Figure 4, bottom). This again suggests
that the cells which had entered the G2/M-phase of the cell
cycle remained there and did not pass through mitosis to
form new GO/G, cells, although a selective kill of GO/GI or
S-phase cells can not be excluded.
Discussion
The studies described in this report show that in vitro
suramin causes a time and dose-dependent accumulation of
MCF-7 human breast cancer cells in the G2/M-phase of the
cell cycle. It can as yet not be excluded from our experiments
that suramin may also partly cause an arrest of the cells in
the G0/Gl-phase of the cell cycle. This may be concluded
from the fact that the fraction ofGO/GI cells seems to plateau
after 48 h in the presence ofsuramin (Figure 4, bottom). This
would be in agreement with the observation that suramin
inhibited DNA synthesis in HeLa cells by direct inhibition of
DNA polymerase activity, thus preventing the initiation stage
of DNA synthesis (Jindal et al., 1990). In addition, this
would be in agreement with the reported observation that
LNCaP human prostate cancer cells arrest in the GO/G,-
phase of the cell cycle upon a 24 h exposure to suramin
(Berns et al., 1990). An accumulation of the LNCaP cells in
the G2/M-phase of the cell cycle could not be expected due to
the short (24h) exposure time to suramin. In the present
study such an accumulation in the G2/M-phase occurred only
after prolonged exposure to suramin. From our experiments,
however, an arrest of the MCF-7 cells in the GO/Gl-phase of
the cell cycle by suramin was not very likely, since after a
24 h exposure to suramin the fraction of GO/G, cells still
decreased, and moreover a significant amount of cells
(26-30%, in the experiment described in Figure 4) was still
able to incorporate bromo-deoxyuridine even after 72 h of
suramin exposure, i.e. were gone into S-phase.
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Figure 3 Effects of suramin alone and in combination with oestradiol or IGF-1 on DNA synsthesis of MCF-7 cells cultured in
serum-free medium. Cells were seeded in complete growth medium and were allowed to attach for 5 h. After subsequent washing
twice with PBS, serum-free experimental medium containing the respective additives was added, and cells were cultured for 24 h
before harvesting and assessment of cell cycle distribution. Results are expressed as the percentage of S-phase cells ± standard
deviation vs suramin concentration.
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Figure 4 Effects of suramin, oestradiol or IGF-1 on the kinetics
ofdistribution of MCF-7 cells in the G2/M-phase and the Go/Gi-
phase of the cell cycle in steroid-depleted serum-containing
medium. Cells were seeded in medium containing dextran-coated
charcoal treated serum. After 24 h incubation to allow attach-
ment of the cells, experimental steroid-depleted serum-containing
medium was added, and cells were cultured for 24, 48 and 72 h
before harvesting and assessment of cell cycle distribution. Experi-
mental medium was renewed every 24 h. The suramin concentra-
tion used was 1 mg ml -1, and the concentrations of oestradiol
and IGF-1 were as indicated in the figures. Results are expressed
as the percentage of G2/M-phase cells (top) or GO/Gl-phase cells
(bottom) ± standard deviation vs duration of culture.
One ofthe major effects attributed to suramin action is the
interference in the binding of growth factors with their cell
membrane receptors (Coffey et al., 1987; Coughlin et al.,
1988; Berns et al., 1990; Pollak & Richard, 1990). The reason
for the observed stimulation of proliferation of some breast
cancer cells at low concentrations of suramin (Foekens et al.,
1992), and the initial (during the first 24 h) dose-dependent
increase in S-phase cells caused by suramin alone, and in the
presence of oestradiol (Figure 3), remains at present unclear.
It could however be a relative effect due to a decrease in the
absolute amount of GO/Gl-phase cells. The lack of an
inhibitory effect of suramin on the oestradiol-induced
stimulation suggests that suramin does not interfere in the
oestradiol-receptor pathway. The short-term stimulation of
suramin on DNA synthesis, i.e. increase in the fraction of
cells in the S-phase, could be due to a nullifying effect of
suramin on a secreted growth inhibitory factor (like trans-
forming growth factor-P, TGF-P) which would act as an
autocrine inhibitor of DNA synthesis. The 50% increase in
S-phase cells by suramin was observed between 10 and
100 igml-' of suramin, and this is in the proximity of the
concentration of ± 50 tgml-' of suramin which caused a
50% inhibition ofTGF-P binding to its receptor on AKR-2B
cells (Coffey et al., 1987).
The observation that suramin causes accumulation or
arrest of MCF-7 cells in the G2/M-phase of the cell cycle may
have beneficial therapeutic consequences in the treatment of
patients in combination therapy with cell cycle specific drugs
or with radiation therapy, known to be most effective on cells
in the late-S and G2/M-phases of the cell cycle.
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